The role of flow cytometry in the classification of myeloid disorders
Author:
Open Access
- 22 November 2023
- journal article
- research article
- Published by Springer Nature in Die Pathologie
- Vol. 44 (S3) , 164-175
Abstract
The World Health Organization classification (WHO-HAEM5) and the International Consensus Classification (ICC 2022) of myeloid neoplasms are based on the integration of clinical, morphologic, immunophenotypic, and genomic data. Flow cytometric immunophenotyping (FCIP) allows the identification, enumeration, and characterization of hematopoietic cells, and is therefore a powerful tool in the diagnosis, classification, and monitoring of hematological neoplasms. The vast majority of flow cytometry (FCM) studies in chronic myeloid neoplasms focus on its role in myelodysplastic neoplasms (MDS). FCM can also be helpful for the assessment of myeloproliferative neoplasms (MPN) and MDS/MPN, including the early detection of evolving myeloid or lymphoid blast crisis and the characterization of monocytic subsets. The classification of acute myeloid leukemia (AML) is primarily based on cytogenetic and molecular findings; however, FCIP is needed for subclassification of AML, not otherwise specified (NOS; ICC)/AML defined by differentiation (WHO-HAEM5). The main role of FCM in AML remains in making a rapid diagnosis and as a tool for measurable residual disease monitoring. Machine learning and artificial intelligence approaches can be used to analyze and classify FCM data. This article, based on an invited lecture at the 106th Annual Meeting of the German Society of Pathology in 2023, reviews the role of FCM in the classification of myeloid neoplasms, including recent publications on the application of artificial intelligence.Keywords
Funding Information
- Karolinska Institute
This publication has 29 references indexed in Scilit:
- Eosinophilia/Hypereosinophilia in the Setting of Reactive and Idiopathic Causes, Well-Defined Myeloid or Lymphoid Leukemias, or Germline DisordersAmerican Journal of Clinical Pathology, 2020
- Myeloid/Lymphoid Neoplasms Associated With Eosinophilia and Rearrangements of PDGFRA, PDGFRB, or FGFR1 or With PCM1-JAK2American Journal of Clinical Pathology, 2020
- Radar plots facilitate differential diagnosis of acute promyelocytic leukemia and NPM1+ acute myeloid leukemia by flow cytometryCytometry Part B: Clinical Cytometry, 2020
- Proliferative activity is disturbed in myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS), and MDS/MPN diseases. Differences between MDS and MDS/MPNCytometry Part B: Clinical Cytometry, 2020
- On Its Way to Primetime: Artificial Intelligence in Flow Cytometry DiagnosticsCytometry Part A, 2020
- Enumeration of CD34+ blasts by immunohistochemistry in bone marrow biopsies from MDS patients may have significant impact on final WHO classificationJournal of Hematopathology, 2020
- Distinguishing myelofibrosis from polycythemia vera and essential thrombocythemia: The utility of enumerating circulating stem cells with aberrant hMICL expression by flow cytometryInternational Journal of Laboratory Hematology, 2018
- Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemiaBlood, 2015
- Flow cytometry immunophenotyping in integrated diagnostics of patients with newly diagnosed cytopenia: one tube 10‐color 14‐antibody screening panel and 3‐tube extensive panel for detection ofMDS‐related featuresInternational Journal of Laboratory Hematology, 2015
- Diagnostic application of flow cytometric characteristics of CD34+ cells in low-grade myelodysplastic syndromesBlood, 2006